in February 1997, and a check of the aircraft records will give a good indication as to whether these filters have been installed on an aircraft.

(c) Special flight permits may be issued for daytime visual flight rules (VFR) flight only, in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location to accomplish the requirement of this AD.

(d) An alternative method of compliance or adjustment of the compliance time that provides an equivalent level of safety may be approved by the Manager, Chicago Aircraft Certification Office, 2300 E. Devon, Des Plaines, Illinois 60018. The request shall be forwarded through an appropriate FAA Maintenance Inspector, who may concur or comment and then send it to the Manager, Chicago Aircraft Certification Office.

Note 4: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Chicago Aircraft Certification Office.

(e) Information related to this AD may be inspected at the FAA, Central Region, Office of the Assistant Chief Counsel, Room 1558, 601 E. 12th Street, Kansas City, Missouri 64106.

(f) This amendment (39–10103) becomes effective on September 18, 1997, to all persons except those persons to whom it was made immediately effective by priority letter AD 97–16–10, issued July 31, 1997, which contained the requirements of this amendment.

Issued in Kansas City, Missouri, on August 14, 1997.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 97–22147 Filed 8–20–97; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Parts 121, 125, 129, and 135

[Docket No. 28109; Amendment Nos. 121–266, 125–30, 129–27, 135–69]

RIN 2120–AF76

Revisions to Digital Flight Data Recorder Rules

AGENCY: Federal Aviation Administration, DOT.

ACTION: Final rule; correction.

Correction

In rule document 97–18514 beginning on page 38362 in the issue of Thursday, July 17, 1997, make the following correction:

FOR FURTHER INFORMATION CONTACT: [Corrected]

1. On page 38362, in the first column, under **FOR FURTHER INFORMATION CONTACT:** in the sixth line, the telephone number ''(202) 267–8096'' should read ''(202) 267–8166''.

Issued in Washington, DC, on August 15, 1997.

Brenda D. Courtney,

Manager, Aircraft and Airports Rules Division.

[FR Doc. 97–22262 Filed 8–20–97; 8:45 am]

BILLING CODE 4910–13–M

RAILROAD RETIREMENT BOARD

20 CFR Part 335

RIN 3220–AB30

Sickness Benefits

AGENCY: Railroad Retirement Board.

ACTION: Final rule.

SUMMARY: The Railroad Retirement Board (Board) hereby amends its regulations under the Railroad Unemployment Insurance Act (RUIA) to permit a substance-abuse professional to execute a statement of sickness in support of payment of sickness benefits under the RUIA.

EFFECTIVE DATE: This rule will be effective September 22, 1997.

ADDRESSES: Secretary to the Board, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611.

FOR FURTHER INFORMATION CONTACT: Thomas W. Sadler, Senior Attorney, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611, (312) 751–4513, TDD (312) 751–4701.

SUPPLEMENTARY INFORMATION: Section 335.2(a)(2) of the Board's regulations provides that in order to be entitled to sickness benefits under the RUIA, a claimant must provide a ''statement of sickness.'' Section 335.3(a) of the Board's regulations lists the individuals from whom the Board will accept a statement of sickness. That list does not currently include a ''substance-abuse professional'' (SAP), although employees may claim sickness benefits under circumstances resulting from alcohol or controlled-substances-related disorders. In providing that an SAP under this part must meet the qualifications outlined in the Department of Transportation (DOT) regulations at 49 CFR part 40.3, the Board recognizes the importance of nationally-accepted standards for SAPs. The DOT regulations define an SAP as a licensed physician (Medical Doctor or Doctor of Osteopathy), a licensed or certified psychologist, a licensed or certified social worker, or a licensed or certified employee assistance professional. The DOT regulations also include alcohol and drug abuse counselors certified by the National Association of Alcoholism and Drug Abuse Counselors (NAADAC) Certification Commission, a national organization imposing qualification standards for treatment of alcohol and drug-related disorders.

Under the DOT regulations, an SAP must have knowledge of, and clinical experience in, the diagnosis and treatment of alcohol and controlled substances-related disorders. Accordingly, those individuals who have the requisite degrees or certificates, but who lack knowledge and clinical experience in alcohol and substance abuse-related disorders, would not meet the criteria of a qualified SAP under this part.

The Board published this rule as a proposed rule on April 18, 1997 (62 FR 19072), and invited comments by June 17, 1997. No comments were received.

The Board, with the concurrence of the Office of Management and Budget, has determined that this is not a significant regulation action for purposes of Executive Order 12866. Therefore, no regulatory impact analysis is required. There are no information collections associated with this rule.

List of Subjects in 20 CFR Part 335

Railroad employees, Railroad sickness benefits.

For the reasons set out in the preamble, title 20, chapter II, part 335 of the Code of Federal Regulations is amended as follows:

PART 335—SICKNESS BENEFITS

1. The authority citation for part 335 continues to read as follows:

Authority: 45 U.S.C. 362(i) and 362(l).

2. Section 335.3(a) is amended by removing ''or'' at the end of paragraph (a)(8) of this section, by removing the period at the end of paragraph (a)(9) of this section and adding ''; or'', and by adding a new paragraph (a)(10) to read as follows:

§ 335.3 Execution of statement of sickness and supplemental doctor's statement.

(a) * * *

(10) A substance-abuse professional as defined in 49 CFR part 40.3, if the infirmity involves alcohol or controlled substances-related disorders.

* * * * *

Dated: August 12, 1997.

By Authority of the Board.

For the Board.

Beatrice Ezerski,

Secretary to the Board.

[FR Doc. 97–22131 Filed 8–20–97; 8:45 am]

BILLING CODE 7905–01–P–M

RAILROAD RETIREMENT BOARD

20 CFR Part 367

RIN 3220–AB26

Collection of Debts

AGENCY: Railroad Retirement Board.

ACTION: Final rule.

SUMMARY: The Railroad Retirement Board (Board) amends its regulations pertaining to the collection of debts by offset against Federal payments to reflect amendments to section 3716 of Title 31 by the Debt Collection Improvement Act of 1996 (Pub. L. 104–134).

DATES: Effective Date: This Regulation will be effective August 21, 1997.

ADDRESSES: Secretary to the Board, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611.

FOR FURTHER INFORMATION CONTACT: Michael C. Litt, General Attorney, Bureau of Law, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611, (312) 751–4929, TDD (312) 751–4701.

SUPPLEMENTARY INFORMATION: Part 367 of the Board's regulations provides for the collection of debts by administrative offset under the authority of the Debt Collection Act of 1982, 31 U.S.C. 3716. The Debt Collection Improvement Act of 1996 (Pub. L. 104–134) amended 31 U.S.C. 3716 to provide for referral of delinquent Federal nontax debts to the Department of Treasury for administrative offset (''Treasury Offset Program''), and to provide for the mandatory referral of such debts over 180 days delinquent to the Treasury Offset Program, subject to certain exceptions. Accordingly, the Board amends this part to implement the provisions of Public Law 104–134.

Section 367.1 is revised to cite the authority of Public Law 104–134 and its provision for the referral of delinquent Federal nontax debts to the Treasury Offset Program.

Section 367.2 is amended to provide that only nontax debts will be referred to the Treasury Offset Program, and that a debt will not be referred if the Board's records show that foreclosure is pending on collateral securing the debt or if the debt has been referred to the Department of Justice or is otherwise in litigation with the Board.

Section 367.3 is amended to provide that the Board shall refer nontax debts over 10 days delinquent to the Treasury Offset Program and that in cases of mandatory referral of delinquent debt, unless otherwise directed by the Secretary of Treasury, the Board is not required to determine whether administrative offset is feasible, allowable, and appropriate.

The Board, with the concurrence of the Office of Management and Budget, has determined that this is not a significant regulatory action under Executive Order 12866. Therefore, no regulatory impact analysis is required. There are no new information collections associated with this rule.

The Board published this rule as an interim final rule on April 21, 1997 (62 FR 19219) and comments were invited by June 20, 1997. No Comments were received. Accordingly, the interim final rule is adopted as a final rule without change.

Dated: August 12, 1997.

By Authority of the Board.

For the Board.

Beatrice Ezerski,

Secretary to the Board.

[FR Doc. 97–22130 Filed 8–20–97; 8:45 am]

BILLING CODE 7905–01–P–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Doramectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer, Inc. The supplemental NADA provides for use of doramectin in cattle to control infections and to protect from reinfection with *Cooperia punctata* and *Dictyocaulus viviparus* for 28 days after treatment. This supplemental NADA also amends the wording of the claim for protection against infection or reinfection with *Ostertagia ostertagi* for 21 days and incorporates the claim into the new indication statement.

EFFECTIVE DATE: August 21, 1997.

FOR FURTHER INFORMATION CONTACT: Thomas Letonja, Center for Veterinary Medicine (HFV–135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1643.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017–5755, is sponsor of NADA 141–061 that provides for the use of Dectomax® 1% injectable solution (doramectin) for treatment and control of certain gastrointestinal roundworms, lungworms, eyeworms, grubs, lice, and mange mites of cattle, and protection against infection or reinfection with *O. ostertagi* for up to 21 days. The firm filed a supplemental NADA that provides for added use in cattle to control infections and to protect from reinfection with *C. punctata* and *D. viviparus* for 28 days after treatment. The supplemental NADA also amends the wording of the claim for ''* * * protection against infection or reinfection with *Ostertagia ostertagi* for 21 days'' and incorporates the claim into the new indication statement. The supplemental NADA is approved as of July 18, 1997, and the regulations are amended in 21 CFR 522.770(d)(2) to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act, this supplemental approval for food-producing animals qualifies for 3 years of marketing exclusivity beginning July 18, 1997, because the supplement contains substantial evidence of the effectiveness of the drug involved, studies of animal safety or, in the case of food-producing animals, human food safety studies (other than bioequivalence or residue studies) required for approval of the supplement and conducted or sponsored by the applicant. Exclusivity applies only to the added indication to control infections and to protect cattle from reinfection with *C. punctata* and *D. viviparus* for 28 days after treatment.

The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.